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  Abstract 
    Objective.   GFR-prediction equations based upon cystatin C and creatinine have better diagnostic performance in  estimating 
GFR than equations based upon only one of the two markers. The present work concerns in what way a comparison 
between separate estimations of GFR based upon cystatin C (eGFR  cystatin C  ) or creatinine (eGFR  creatinine  ) can be used to 
evaluate the diagnostic performance of a combined cystatin C- and creatinine-based estimation of GFR.   Methods.   The 
difference between eGFR  cystatin C   and eGFR  creatinine   was compared with measured GFR (iohexol clearance) and a combined 
cystatin C- and creatinine-based estimation of GFR in a Swedish-Caucasian cohort of 857 adult patients.   Results.   
A   difference between eGFR  cystatin C   and eGFR  creatinine    of       40% indicated a markedly reduced diagnostic performance 
of the combined cystatin C- and creatinine-based estimation of GFR.   Conclusion.   Comparison of the agreement between 
eGFR  cystatin C   and eGFR  creatinine   can be used to evaluate the diagnostic performance of combined cystatin C- and 
  creatinine-based estimations of GFR. If   ‘  threshold values  ’   for discordance are exceeded, it must be considered whether the 
clinical context requires the use of an invasive gold standard method to measure GFR. In some clinical contexts either 
creatinine or cystatin C are known to be invalidated as markers of GFR and in these situations the use of only the cystatin 
C- or the creatinine-based GFR estimate should be considered when the   ‘  threshold values  ’   are exceeded.   
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    Introduction 
  GFR-prediction equations based upon cystatin C 
(eGFR  cystatin C  ) or creatinine (eGFR  creatinine  ) may 
produce estimated GFR-values, of which 80  –  85% 
are within        30% of GFR measured by invasive 
gold standard methods. However, the highest 
percentages of estimated GFR-values within       30% 
of measured GFR are obtained using   GFR-prediction 
equations based upon both cystatin C and creatinine 
(eGFR  cystatin C       creatinine  ) [1  –  9]. The performance 
of eGFR  creatinine   is reduced   inter alia   if a patient has 
an abnormally low or high muscle mass, recently 
ingested boiled meat or is treated with a drug 
that inﬂ   uences the tubular secretion of creati-
nine. The performance of eGFR  cystatin C   is reduced 
  inter alia   if a patient is treated with large doses of 
glucocorticoids. In such clinical situations the diag-
nostic performance of a GFR-prediction equation 
based upon both cystatin C and creatinine may be 
inferior to those equations based upon only one of the 
GFR-markers [1]. See also www.egfr.se. However, 
such situations may not always be recognized by those 
ordering a   GFR-estimate or by the laboratory per-
forming the tests. It has therefore been suggested that a 
comparison between separate estimations of GFR based 
upon cystatin C or creatinine can be used to evaluate 
the diagnostic performance of a combined cystatin 
C- and creatinine-based estimation of GFR [1]. The 
present work concerns the relation between the agree-
ment between eGFR  cystatin C   and eGFR  creatinine   and 
the diagnostic performance of eGFR  cystatin C       creatinine  .     
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  Material and methods 
  The patient population studied was identical to the 
one previously used to analyse various equations 
to combine creatinine and cystatin C to predict 
GFR [8]. It consisted of adult patients (Swedish-
Caucasians       18 years) consecutively referred to 
the Departments of Clinical Chemistry,   University 
Hospitals of Lund and Malm  ö   for   determination 
of GFR by iohexol   clearance. Simultaneous 
measurements of plasma creatinine, plasma cystatin 
C, weight and height were performed and age and 
gender recorded. 
  The Lund population consisted of 451 patients 
(225 females) and the Malm  ö   population of 
425 patients of whom 19 patients were excluded 
because of missing plasma creatinine values (  n       6), 
missing plasma cystatin C values (  n       8) or technical 
assay errors ( n       5) leaving 406 subjects in the Malm ö   
cohort. All procedures involving subjects and data 
were in accordance with the Helsinki Declaration of 
1975 concerning ethical principles for medical 
research involving human subjects. 
  The characteristics of the two cohorts and the 
combined set (  n        857) are shown in Table I and 
included 12 patients with neurological diseases and 
secondary muscular atrophy. Common indications 
for referral were diagnosis and follow-up of chronic 
kidney disease, evaluation of renal function prior to 
dosage of drugs cleared by the kidneys, evaluation of 
potential renal donors, follow-up of unilaterally 
nephrectomized patients, pre-operative evaluation of 
patients with hyperparathyroidism and control of 
renal transplants (  n       44).  
  Determination of iohexol clearance 
  Five mL of iohexol (Omnipaque 300 mg iodine/mL, 
GE Healthcare, Oslo, Norway) were administered 
intravenously in an antecubital vein. Iohexol clear-
ance (referred to as   ‘  measured GFR  ’  ) was   calculated 
from plasma clearance of a single plasma sample of 
iohexol [10] drawn at varying times,   normally 
4 hours after injection, according to expected GFR 
as determined by plasma creatinine   concentration 
and   anthropometric data. The exact time of 
  administration and blood sampling were documented 
by a   specialist nurse. Plasma iohexol concentrations 
were determined by high-pressure liquid chromatog-
raphy with a total analytical variation of 2  –  4% (coef-
ﬁ  cient of variation, CV%) at the range of iohexol 
concentrations normally encountered during the 
study [11]. The Dubois formula was used to adjust 
the measured GFR values to 1.73 m  2   body surface 
area [12].     
  Determination of plasma creatinine 
  Plasma concentrations of creatinine were determined 
at Lund University Hospital by an enzymatic colori-
metric assay on a Hitachi Modular P analyzer (Roche 
Diagnostics, Mannheim, Germany) and with a cali-
brator traceable to primary reference material with 
values assigned by isotope dilution mass spectrom-
etry (IDMS) [13]. At Malm  ö   University Hospital a 
modiﬁ   ed Jaffe colorimetric method was used on 
a Beckman LX20 analyzer (Beckman Coulter, Inc., 
Fullerton, CA, USA) employing zero-point calibra-
tion and a calibrator traceable to primary reference 
material with values assigned by IDMS [14,15]. Total 
analytical variation (CV%) of the enzymatic method 
in Lund was 1.4  –  3.0% at concentrations of creati-
nine between 60 and 578   μ  mol/L and 2.2  –  2.8% at 
concentrations between 53 and 631   μ  mol/L for the 
Jaffe method in Malm  ö  .     
  Determination of plasma cystatin C 
  Plasma cystatin C levels were determined by an auto-
mated particle-enhanced immunoturbidimetric 
method [16] using a Hitachi Modular P analysis sys-
tem, reagents (code Nos LX002, S2361, X0973, 
X0974) obtained from DakoCytomation (Glostrup, 
Denmark) and following the procedure recom-
mended by the reagent producer. The procedure had 
a total coefﬁ  cient of variation of 2.1% at a cystatin 
C level of 1.0 mg/L and of 1.7% at a level of 
4.0 mg/L. All samples were analysed within one day 
after collection or frozen at   –  20  °  C until analysed.     
    Table I. Demographic and anthropometric patient characteristics, plasma creatinine, plasma cystatin C, and iohexol clearance given as 
median values (2.5 and 97.5 percentiles) in the Lund and Malm  ö   cohorts as well as in the combined set.   
Parameters Lund     (  n       451) Malm ö       (  n       406) Combined     (  n       857)
Age (years) 58     (24  –  83) 61     (26  –  85) 59     (26  –  85)
Females 225     (50%) 152     (37%) 377     (44%)
Total body weight (kg) 73     (46  –  115) 78     (49  –  111) 75     (48  –  112)
Height (cm) 170     (151  –  189) 173     (152  –  190) 171     (152  –  189)
Body surface area (m  2  ) 1.83     (1.45  –  2.31) 1.92     (1.49  –  2.33) 1.88     (1.46  –  2.31)
Body mass index (kg/m  2  ) 25     (18  –  39) 26     (18  –  38) 25     (18  –  38)
Plasma creatinine (  μ  mol/L) 92     (39  –  400) 136     (54  –  623) 106     (44  –  545)
Cystatin C (mg/L) 1.18     (0.79  –  3.07) 1.53     (0.85  –  4.06) 1.30     (0.81  –  3.82)
Iohexol clearance (mL/min per 1.73 m  2  ) 63     (11  –  124) 42     (8  –  115) 55     (9  –  121)     eGFR    CC     - eGFR    creat     comparison and eGFR       75
  Prediction equations 
  The Lund-Malm  ö   creatinine-based equation 
(eGFR  creatinine  ) with age and gender [17] and the 
Grubb cystatin C-based equation (eGFR  cystatin C  ) 
based on adults and including gender [2] were 
selected for the present analysis. Plasma creatinine 
(pCr) is expressed in   μ  mol/L, plasma cystatin 
C (pCy) in mg/L, age in years and ln denotes the 
natural logarithm. Both equations express relative 
GFR in mL/min per 1.73 m  2   body surface area.     
  Lund-Malm  ö   creatinine equation (eGFR  creatinine   ) 
  GFR     e X     0.0124     age     0.339     ln(age)      0.226 (if female) 
  X     4.62     0.0112      pCr (if pCr       150   μ  mol/L) 
  X      8.17      0.0005      pCr      1.07      ln(pCr) (if 
pCr     150   μ  mol/L)     
  Grubb cystatin C equation (eGFR  cystatin C    ) 
  GFR     86.49     pCy–1.686      0.948 (if female),    
 equivalent  with 
  GFR     e 4.46     1.686     ln(pCy)      0.053 (if female) 
  GFR estimates from the combined use of the two 
analytes (eGFR  cystatin C       creatinine  ) were based on the 
arithmetic mean of eGFR  cystatin C   and eGFR  creatinine  , 
which has proved as accurate as more complex 
  equations [8].     
  Statistical evaluation 
  All statistical analyses were conducted using SPSS 
release 18.0.1. (SPSS Inc, Chicago, USA). In the 
statistical testing we regarded   p  -values in the order 
of 0.05 as moderate evidence against the null hypoth-
esis, whereas   p  -values in the order of 0.001 or below 
were regarded as strong evidence against the null 
hypothesis [18]. The present study focused on the 
  accuracy   of the arithmetic mean of eGFR  cystatin C   and 
eGFR  creatinine,   denoted eGFR  cystatin C      creatinine  , in rela-
tion to the   agreement   between eGFR  cystatin C   and 
eGFR  creatinine  . The  accuracy   of eGFR  cystatin C      creatinine   
was reﬂ  ected by the absolute percentage error: 
  |eGFR  cystatin C     creatinine       measured GFR| / measured 
GFR,     and summarized as the percentage of 
estimates within 30% (P 30  ) and 10% (P 10  ) of measured 
GFR [19]. The   agreement   was reﬂ   ected by the 
difference%, i.e. the absolute difference |eGFR  cystatin C     
   eGFR creatinine  | expressed in percent relative to the 
arithmetic mean eGFR  cystatin C       creatinine  . 
  The following analyses were made: 
      (1) Pearson  ’  s and Spearman  ’  s correlation 
coefﬁ  cients (denoted r and r  s  ) were used to 
evaluate the overall association between 
accuracy (absolute percentage error) and 
agreement (difference%).   
    (2)  The accuracy categorized as P  30   and P  10   was 
evaluated in relation to agreement (differ-
ence%) rounded to nearest integer and then 
categorized  as      10%,  10 –  19%, 20  –  29%, 
30  –  39% and      40% difference. Fisher ’  s exact 
test was used to evaluate differences in P  30   
and P  10   across categories of agreement.   
    (3)  Measured GFR is related to both accuracy 
and agreement and may thus confound the 
association between agreement and accuracy. 
To account for such confounding we mod-
elled accuracy, i.e. P  30   and P  10  , respectively, 
using logistic regression with measured GFR 
and difference% as continuous covariates.   
    (4) We calculated an   ‘  improvement index  ’  , 
deﬁ  ned as the proportion of all GFR esti-
mates for which eGFR  cystatin C       creatinine  , but 
not both eGFR  cystatin C   and eGFR  creatinin  , 
were inaccurate according to P  30   and P  10  , 
respectively. This index represents the upper 
limit of the improvement in accuracy that 
could be obtained if the most accurate eGFR 
(i.e. eGFR  cystatin C       creatinine  , eGFR  cystatin C   or 
eGFR  creatinin  ) was consistently applied for 
each patient. Note that the sum of, e.g. P  30   
and the corresponding improvement index 
for P  30   can never exceed 100%.   
    (5)  The improvement index depends on the 
accuracy, i.e. the potential for improvement 
is higher when accuracy is low. To account 
for such confounding in the association 
between agreement and the improvement 
index, we modelled the improvement index 
using logistic regression with inaccuracy 
(absolute percentage error) and difference% 
as continuous covariates.           
  Results 
  The overall association between difference% and 
absolute percentage error was not consistent (r     0.13, 
  p        0.001 but r  s       0.05,   p        0.12), however, P  30   was 
clearly decreased for differences between eGFR  cystatin C   
and eGFR  creatinin   exceeding a   ‘  threshold value  ’   of 
40% (Table II;   p        0.02 when comparing P  30   for 
30  –  39  and       40% difference). The dip in accuracy 
when expressed as P  10   seemed to occur already at 
30  –  39% difference, but the statistical evidence for 
this dip was weak (  p       0.09 when comparing P  10   for 
20  –  29 and 30  –  39% difference). Measured GFR was 
noticeably lower for differences exceeding 40%, but 
the suggested inverse association between differ-
ence% and P  30   remained clear when measured GFR 
was adjusted for using logistic regression (  p       0.001), 
whereas the association between difference% and P  10   
remained weaker (  p       0.05). 76     A. Grubb et al.     
  The improvement index generally suggested 
higher potential for improvement in accuracy 
when the difference between eGFR  cystatin C   and 
eGFR  creatinin   was considerable (Table II). This asso-
ciation between the agreement (difference%) and the 
potential for improvement in accuracy remained 
  evident when differences in accuracy across levels of 
agreement were adjusted for using logistic regression 
(  p        0.001 both for improvement in P  30   and in P  10  ).     
  Discussion 
  The diagnostic performance of eGFR  creatinine   is 
reduced   inter alia   if a patient has an abnormally low 
or high muscle mass, recently ingested boiled meat 
or is treated with a drug that inﬂ  uences the tubular 
secretion of creatinine. In these clinical contexts the 
diagnostic performance of eGFR  cystatin C   is generally 
unaltered. However, the performance of eGFR  cystatin C   
is impaired if a patient is treated with large doses of 
glucocorticoids and in this situation the performance 
of eGFR  creatinine   is still acceptable. Although 
GFR-prediction equations based upon both cystatin 
C and creatinine (eGFR  cystatin C       creatinine  ) generally 
are superior to GFR-prediction equations based 
upon either cystatin C (eGFR  cystatin C  ) or creatinine 
(eGFR  creatinine  ) this may not be the case in these 
speciﬁ   c clinical contexts. Although these contexts 
may be easily   recognized in some cases, they will 
not invariably be recognized. There may also 
be additional, not yet identiﬁ   ed, clinical contexts 
invalidating either cystatin C or creatinine as useful 
markers for GFR. Comparing eGFR  cystatin C   and 
eGFR  creatinine   might be helpful to identify both known 
and unknown causes when neither cystatin C nor 
creatinine are suitable as a marker for GFR [1]. 
To be able to efﬁ   ciently use such a comparison, 
it must be known when the discordance between 
eGFR  cystatin C   and eGFR  creatinine   is large enough to 
indicate such a condition. The present study 
based upon measured GFR and eGFR  cystatin C   and 
eGFR  creatinine   in a patient cohort of 857 
  Swedish-Caucasian adult patients indicates that if 
the discordance is 40% or more, the diagnostic 
performance of eGFR  cystatin C       creatinine   is markedly 
reduced. Such discordance should initiate a more 
careful evaluation of the clinical context to disclose 
conditions invalidating either creatinine or cystatin 
C as a GFR marker. If such conditions are identiﬁ  ed, 
GFR might be best estimated using a prediction 
equation based upon only the non-invalidated 
marker. If such conditions are not identiﬁ  ed, 
it should be realized that the estimation of GFR 
is unreliable and that an invasive, gold standard, 
measurement of GFR might be required. 
  It should be realized, that the discordance value, 
the   ‘  threshold value  ’  , indicating requirement of a 
further evaluation of the clinical context to improve 
estimation of GFR, as presented in this work, is inﬂ  u-
enced by the actual patient cohort and by the equa-
tions used for estimating GFR, i.e. eGFR  cystatin C  , 
eGFR  creatinine   and eGFR  cystatin C       creatinine  . For other 
patient cohorts might contain proportionally more, 
or fewer patients, with conditions invalidating either 
cystatin C or creatinine as a GFR marker. The more 
patients with such conditions in the cohort, the 
greater the potential for improvement of eGFR by 
comparison of eGFR  cystatin C   and eGFR  creatinine  . The 
equations for eGFR  cystatin C  , eGFR  creatinine   and 
eGFR  cystatin C      creatinine   will also inﬂ  uence the   ‘  thresh-
old value  ’   by being more or less sensitive for patient 
characteristics reducing the value of creatinine and 
cystatin C as markers for GFR. 
  It is possible to calculate an   ‘  improvement 
index  ’  , deﬁ  ned as the proportion of all GFR esti-
mates for which eGFR  cystatin C       creatinine  , but not 
both eGFR  cystatin C   and eGFR  creatinin  , are inaccurate 
according to P  30   or P  10  . This index will represent 
the upper limit of improvement in accuracy that 
could be obtained, if the most accurate eGFR (i.e. 
eGFR  cystatin C      creatinine  , eGFR  cystatin C   or eGFR  creatinin  ) 
was consistently applied. In the present study the 
improvement index was 18.3 % for a discordance 
threshold  of        40%, which means that if an accu-
rate evaluation of the relevant clinical conditions 
could be performed for each patient the P  30  -value 
of 79.6% for eGFR  cystatin C       creatinine  , would 
    Table II. Accuracy of eGFR  cystatin C       creatinine  , the arithmetic mean of eGFR  cystatin C   and eGFR  creatinine  , calculated as the percentage of 
estimates within 30% (P  30  ) and 10% (P  10  ) of measured GFR in relation to the difference% between eGFR  cystatin C   and eGFR  creatinine  , 
deﬁ  ned as |eGFR  cystatin C       eGFR  creatinine  | / eGFR  cystatin C      creatinine  . The improvement index, deﬁ  ned as the proportion of all GFR estimates 
where eGFR  cystatin C       creatinine  , but not both eGFR  cystatin C   and eGFR  creatinin  , were inaccurate within 30% and 10% of measured GFR, 
is also presented.   
Difference %
Median measured GFR 
(mL/min per 1.73 m  2  )
Accuracy (%) Improvement index (%)
30% 10% 30% 10%
     10  ( n       220) 59 90.0 43.6 1.8 8.2
10  –  19 (  n       200) 59 91.5 48.5 2.5 25.0
20  –  29 (  n       175) 61 94.3 45.1 5.7 39.4
30  –  39 (  n       120) 54 90.0 35.0 8.3 52.5
     40  ( n       142) 39 79.6 40.8 18.3 30.3
Total (  n       857) 55 89.5 43.4 6.4 28.4     eGFR    CC     - eGFR    creat     comparison and eGFR       77
theoretically increase to 79.6       18.3     97.9%. 
This   ‘  improvement index  ’   will, exactly like the 
  ‘  threshold value  ’   of discordance, also be inﬂ  uenced 
by the actual patient cohort and by the equations 
used for eGFR, i.e. eGFR  cystatin C  , eGFR  creatinine   and 
eGFR  cystatin C       creatinine   and for the same reasons.     
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